Please assess the completion status of the following clinical trial:

Trial Title: Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must agree to a follow-up visit at approximately 4-8 weeks gestation and a follow up phone call at 20 and 40 weeks gestation/livebirth. For patients assigned to the TEST group must agree to PGD testing and collection of buccal swab sample on newborn~* At least 10 eggs retrieved~* Must agree to use only Ferring products during stimulation~* Normal uterine cavity detected on hysterosalpingogram (HSG), saline infusion sonogram (SIS), or hysteroscopy~* Signed consent form~Exclusion Criteria:~* FSH ≥10 IU/L within past year prior to screening~* 2 or more previously failed IVF cycles~* Gestational or surrogate carrier, donor oocyte, donor sperm~* History of recurrent pregnancy loss (3 or more consecutive miscarriages)~* Severe male factor infertility defined as ejaculate sperm of \< 1million sperm/ml, or sperm obtained through testicular biopsy~* Gender selection as primary indication~* Maternal disease that is not clinically stable and known to impact the ability to become pregnant or carry a pregnancy to term (lupus, chronic liver or kidney disease, body mass index (BMI) \>35, uncontrolled hypertension, anti-phospholipid antibody, thrombophilia, insulin dependent diabetes)~* Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests~* Participation in any experimental drug study within 30 days prior to Screening~* Prior hypersensitivity to any of the protocol drugs~* Known history conveying increased risk for chromosome abnormality (beyond maternal age) or genetic disease in offspring

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- CONTROL arm (Type: NO_INTERVENTION): Subjects assigned to this arm of the study will receive no PGS testing.
- TEST arm (Type: OTHER): Subjects assigned to this arm of the study will receive PGS testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).